A r t i c l e s CRISPR-based genome editing has considerable therapeutic potential in a wide range of diseases [1] [2] [3] [4] [5] . A key challenge is achieving efficient, clinically suitable delivery of genome editing macromolecules. CRISPR-Cas9, a complex of the RNA-guided nuclease (Cas9) and a single guide RNA (sgRNA) 2 , recognizes a protospacer-adjacent motif (PAM) and a 20-nucleotide sequence in the genome by Watson-Crick base pairing 2-5 and generates double-stranded DNA breaks (DSBs), which are repaired by endogenous cellular mechanisms such as homology-directed repair (HDR) and nonhomologous end-joining (NHEJ) 5 . Long-term expression of Cas9-sgRNA in vivo has been shown using viral vectors, including adeno-associated virus (AAV) 6-9 . However, an ideal CRISPR-Cas9 delivery system would limit the duration of exposure to the editing machinery to minimize potential off-target effects 10 . In addition, spCas9, the most commonly used form of Cas9, is difficult to fit in typical AAV constructs with strong promoters 6 . Although a smaller form of Cas9 was packed into a single AAV construct 11 , concerns regarding potential off-target effects remain when Cas9 is stably expressed by AAV delivery 12 . Moreover, the immune response to AAV capsids can limit repeat dosing in patients 13, 14 , and the long-term presence of Cas9, a bacterial protein, in human tissue also increases the risk of immunogenicity 13, 15 . These limitations can be addressed using non-viral delivery systems 12 . The use of Cas9-sgRNA ribonucleoprotein (RNP) has been tested in cell culture and for local delivery in mouse inner ear cells 16 but has not yet been demonstrated for systemic in vivo delivery. Previously, we used lipid nanoparticle (LNP)-encapsulated Cas9 mRNA in combination with an AAV carrying a sgRNA and a repair template for efficient genome editing in the mouse liver 12 . However, to our knowledge, a fully non-viral, systemic Cas9 genome editing system allowing efficient in vivo gene modification has not been described 17 .
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A r t i c l e s function through the use of RNase H, show a different pattern of sensitivity to chemical modifications 19 .
Targeting of the Cas9 complex is guided by sgRNAs, which combines CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA) 2 . These sgRNAs are about 100 nucleotides (nt) long, with 20 nt at the 5′ end hybridizing the complementary DNA sequence and the remaining structure for Cas9 recognition and binding [2] [3] [4] [5] . Chemical modification of three nucleotides at both the 5′ and 3′ ends has been shown to improve genome editing efficiencies in vitro in human cells 22 . Rational chemical modifications of crRNA in combination with unmodified tracrRNA mediated effective genome editing in human cells 23 . However, in these studies the majority of the RNA remained unmodified, and the potential of using these chemical modifications in vivo was not explored 22, 23 . We reasoned that in vivo application of sgRNA would benefit from focused chemical modification.
Guided by the structure of the Cas9-sgRNA complex, we here develop enhanced sgRNA (e-sgRNA), defined as 70 out of 101 nt of sgRNA modified with a 2′ hydroxyl (OH) group, and a number of phosphorothioate bonds. We identify regions of sgRNA that tolerate chemical modification without inhibiting the interaction of Cas9 and sgRNA while maintaining or enhancing genome editing activity. Using these modifications, we demonstrate that a single dose of the formulated e-sgRNA and Cas9 mRNA allows for nearly complete editing of the target gene in hepatocytes in vivo.
RESULTS
Structure-guided chemical modification of sgRNA's invariable part
To study the modifications tolerated by sgRNA, we separately analyzed its invariable and variable parts. The variable part, as the guide sequences, is the region of 1-20 nucleotides from the 5′ end (Fig. 1a) . The invariable part is 21 to 101 nucleotides from the 5′ end, including the bona fide Cas9 protein-binding region and the tail region (Fig. 1a) . We first synthesized sgRNAs containing the guide sequence targeting GFP protein 24 .
To more rapidly identify modifications that were tolerated by the sgRNA, we made use of a cell reporter system to test the editing efficiency of modified sgRNAs. HEK293 cells were engineered to stably express GFP and spCas9 (Fig. 1a) . Introducing a functional sgRNA targeting GFP abrogates the expression of GFP through the generation of frameshifting indel mutations (Fig. 1a) . If a pattern of chemical modifications on the sgRNA is not well tolerated, such chemically modified sgRNA induces fewer GFP-negative cells (GFP − ) than unmodified sequence. We generated a number of sgRNAs modified with 2′F RNA, 2′OMe RNA and the phosphorothioate bond (PS) 25 ( Fig. 1b) at different positions (Fig. 1c) . Native sgRNA targeting GFP efficiently generated GFP − cells (82.3% ± 1.7%) with a relatively high dose of sgRNA transfected (1 µg/mL; Fig. 1c and Supplementary  Fig. 1 ). By contrast, 2′F modification of "U" and "C" on the Cas9 binding region nearly abolished the editing effect of the GFP sgRNA. Furthermore, when we substituted all of the U and C with 2′F modified U and C in the Cas9 binding region and tail region (2′F, U&C mod 21-101nt), the editing ability of the sgRNA was totally eliminated, as indicated by background level of GFP − cells after transfection (Fig.  1c) . To examine whether the Cas9 binding and tail region can tolerate full substitutions of other chemical modifications, we introduced 2′OMe (2′OMe, 21-101nt) or PS modification (PS, 21-101nt) to all nucleotides or all phosphodiester bonds at the invariable part of sgRNA. Complete modification of the invariable part of sgRNA also totally destroyed its function (Fig. 1c) . The loss of genome editing ability was further demonstrated by tracking of indels by decomposition (TIDE) analysis and T7EI assays of the amplicon from the GFP locus (Supplementary Fig. 1 ). These data indicate that the invariable part of the sgRNA cannot be fully modified, and that certain partial modifications can also abolish the function of the sgRNA.
To better identify regions of the sgRNA that might tolerate or be sensitive to chemical modification, we designed patterns of sgRNA chemical modifications guided by the structure of the Cas9-sgRNA complex 26, 27 . These structural biology studies demonstrated that the tetraloop and the second stem-loop of sgRNAs extend outside of the Cas9 protein. We hypothesized that these two loops could tolerate modifications in all nucleotides, as long as those modifications did not inhibit loop formation. Indeed, the sgRNA carrying the 2′ OMe (2′OMe, Loops) modification at these two loops was functional, and, in fact, it showed a small but significant increase of editing efficiency (89.3% ± 0.3% of GFP − cells, P < 0.001; Fig. 1d) . Notably, incorporating 2′F-modified RNA into these two loops significantly decreased the activity of sgRNA in cells (42.4% ± 0.5% of GFP − cells; P < 0.001) (Fig. 1d) . It is possible that the 2′F modification within loops influences their secondary structure 28 . For this reason, we focused on the 2′ OMe modification for the invariable part of sgRNA during the following studies.
Further review of the structure of the Cas9-sgRNA complex 26, 27 showed that ~20 nucleotides in the invariable region of sgRNA interact with the Cas9 protein at the 2′ hydroxyl (OH) group, mostly through hydrogen bonds (Fig. 1a and Supplementary Table 1) . We hypothesized that if we avoided modifying these 'interacting' 2′ OH groups, and instead modified the remaining nucleotides that did not interact with Cas9 protein at the 2′OH with 2′OMe, then this structure-guided (SG) chemical modification pattern would retain the genome editing activity of sgRNA. Strikingly, this comprehensive, heavily modified sgRNA (named as SG-2′OMe), in which 60 out of 81 nucleotides were modified with 2′OMe RNA, fully retained its activity in cells with a moderate increase in editing efficiency (Fig. 1e) . In contrast, a 2′OMe modification at all nucleotides of the invariable region or selectively at the 'interacting' 2′OH groups (Reverse-SG-2′OMe) fully abolished the genome editing activity of sgRNA (Fig. 1c,e) .
Next, we sought to combine two different chemical modifications, the 2′OMe and the PS. Because the PS modification of all phosphodiester bonds at the invariable part abolished the activity of sgRNA (Fig. 1c) , we decided to modify part of the tail region, which has minimal interaction with Cas9 protein (PS_70-101nt). This partial PS modification maintained the sgRNA's activity, with a slight increase in activity over the native strand (Fig. 1e) . We then combined the patterns of PS (PS_70-101nt) with 2′OH modification (SG-2′OMe). The combined modification pattern (SG-2′OMe-PS) on the sgRNA significantly enhanced genome editing in cells (96.2% ± 0.5% GFP − cells; P < 0.001).
Structure-guided chemical modification of guide sequences
To explore the rules of chemical modifications at the variable part (the guide sequences), we used a crRNA/tracrRNA system (Fig. 2a) to reduce synthetic cost. We first measured the efficiency of crRNA modified at all nucleotides in the guide sequence with the 2′OMe modification (2′OMe_1-20nt). We found that full-length modification at the guide sequence with 2′OMe abolished its function (Fig. 2b) . We next sought to explore modification of half of the nucleotides in the guide sequence. We modified 1-10 nt or 11-20 nt, as the tail or seed region, respectively (Fig. 2a) . We found that the modification of all nucleotides in the seed region abolished the activity of crRNA in cells (Fig. 2b) and the modification of all nucleotides in the tail region also decreased its editing efficiency (Fig. 2b) . Based on the structure of sgRNA-Cas9 in the region of guide sequence (Fig. 2a) , we identified five nucleotides that interact with Cas9 at their 2′OH group. Among them, four sites are located at the seed region and one at the tail region (Supplementary Table 1 ). Therefore, we designed two crRNAs, both with a modification of five nucleotides at the seed region and modification of another five nucleotides at the tail region. The first design avoided modifying these 2′ OH interacting sites (SG2′OMe_1-20nt), whereas the second design intentionally modified all the interacting sites (Reverse-SG-2′OMe_1-20nt) (Fig. 2a) . We found that crRNA SG-1-20nt-2′OMe, which contained 10 2′OMe-modified nucleotides but avoided the modification of the interacting sites, fully retained its activity (Fig. 2b) . By contrast, modification of the interacting 2′OH abolished the activity of crRNA in cells (Fig. 2b) .
To examine whether 2′F RNA modification on the guide sequence displayed a similar function, we synthesized crRNA with the same designed patterns, but replaced 2′OMe with 2′F. The 2′F modification on the guide sequence followed a similar pattern as the 2′OMe modification (Fig. 2c) . The full-length modification of 2′F (2′F_1-20nt) or "half modification" on the seed region (2′F_11-20nt) significantly decreased, but did not abolish, its function as happened with the 2′OMe modification. We noted that the physical size of F is smaller than OMe, and there are substantial electronic differences between F and OMe as well, for example, F, but not OMe, can serve as a very weak hydrogen bond acceptor 19, 29 , thus, it is possible that modification by 2′F is more compatible with Cas9 binding than 2′OMe.
To identify whether modifications of 2′OH groups and phosphate in the guide sequence can be combined, we first modified the guide sequence with PS only. We found that modification of all 20 nucleotides with PS significantly decreased the activity of crRNA (PS_1-20nt) (Fig. 2d) . Based on the crystal structure, a number of sgRNA phosphates interact with the Cas9 protein (Supplementary Table 2 ). We therefore sought to avoid modifying these phosphates while replacing others with PS in the guide sequence. This crRNA (SG-PS_ 1-20nt) exhibited significantly (P < 0.05) higher potency of genome editing than unmodified crRNA (Fig. 2d) .
We then combined the PS with the 2′OMe or the 2′F pattern of modifications described above (Fig. 2e) . The combination of the 2′F and PS (SG-PS-2′F) significantly (P < 0.05) increased the activity of crRNA, but the combination of the 2′OMe and PS at the guide region (SG-PS-2′OMe) was not tolerated (Fig. 2e) . Thus, we decided to combine the 2′F and PS on the guide sequences for further studies. Because this design did not fully modify the 5′ end of the crRNA, to prevent cleavage by exonucleases, the first three nucleotides at the 5′ end were modified with 2′ OMe and PS, or 2′F and PS, in combination with the pattern of SG-PS-2′F_1-20nt in the guide region. We found the combination (5′-PS-2′OMe_SG-PS-2′F) resulted in slightly higher editing efficiency than the second combination (5′-PS-2′F_SG-PS-2′F) (Fig. 2e) , thus, we decided to use the first pattern for the guide sequence.
To explore whether such a pattern of modification (5′-PS-2′OMe_ SG-PS-2′F; Fig. 2e ) can be used for guide sequences targeting other genes, we synthesized additional crRNA sequences, targeting human genes HBB (hemoglobin subunit beta) and EXM1 (empty spiracles homeobox 1), with and without the above developed chemical modification pattern on the guide sequences (Fig. 2f) . We found that this Figure 1a were incubated with crRNA in (b-e) and an unmodified tracrRNA. FACS was performed to determine the ratio of GFP − cells. (f) crRNAs targeting HBB and EMX-1 were chemically modified with patterns described in e (5′-PS-2′OMe_SG-PS-2′F), and TIDE analysis was performed to determine indels at the HBB and EMX-1 loci, respectively. (g) crRNAs targeting GFP with modifications of single or multiple 2′OH in the guide region. TIDE analysis was performed to measure indels at GFP locus. *P < 0.05. (n = 4 in f and g, and n = 3 in others), error bars as s.d.
pattern of modification enhanced the formation of indels 2-to 3-fold compared to unmodified crRNAs (Fig. 2f) .
To understand whether modifications of individual nucleotide on the variable part could affect the potency of genome editing, crRNAs with modifications at one or several 2′OH groups in the guide sequences were synthesized and evaluated (Fig. 2g) . The substitution of even a single 'interacting' 2′OH with 2′OMe significantly decreased or even abolished the activity of crRNA (Fig. 2g) . By contrast, the substitution of three non-'interacting' 2′OH with 2′F significantly increased the editing efficiency of the crRNA (Fig. 2g) .
Evaluating e-sgRNA in cells Next, we sought to combine modifications at the variable and invariable parts (Fig. 3a) . We compared the editing efficiency of (1) unmodified sgRNA-targeting GFP (native sgRNA), (2) a published chemical modification of both the 5′ and 3′ ends (2′OMe and PS modifications of 3 nt at the 5′ and 3′ end, respectively, named as 5′&3′-sgRNA) 22 , and (3) the pattern of 'enhanced' chemical modification, generated by combining the patterns of modification shown in Figures 1e and 2e , that we term e-sgRNA. Cas9 mRNA and one of these three sgRNAs were delivered to HEK293 cells expressing GFP (Fig. 3b) . This e-sgRNA generated a significantly higher number of indels than the 5′&3′-sgRNA and the native sgRNA (43%, 22% and 20%, respectively). In contrast, as previously discussed, native sgRNA transfected into cells already expressing Cas9 induced potent GFP knockout (82.3% ± 1.7%) (Fig. 1c and Supplementary Fig. 1 ). We hypothesize that the modifications of e-sgRNA facilitate function in part by increasing RNA resistance to degradation, which thereby allows persistence while Cas9 mRNA is translated.
To investigate whether this pattern of sgRNA modification can be applied to target other genes, we synthesized e-sgRNA targeting the human HBB gene. When delivered with Cas9 mRNA, unmodified HBB sgRNA, 5′&3′-sgRNA and e-sgRNA generated an undetectable percentage, ~15% and ~50% indels, respectively (Fig. 3c) . To investigate whether e-sgRNA altered off-target activity, we measured offtarget frequencies of HBB sgRNA at three predicted genomic loci 22 . For two of the three predicted sites, no off-target activity was found for any of these sgRNAs. Off-target cleavage at site 1 was observed, as previously reported 22 . However, although the HBB e-sgRNA produced higher off-target activity at site 1 (Fig. 3d) , the off-target/ on-target indel frequency ratios remained similar among all three tested sgRNAs.
Cas9 protein may partially protect bound sgRNA from degradation 22 . To investigate whether higher activity of e-sgRNA is observed when Cas9 protein was presented before delivery of sgRNA, different doses of unmodified RNA, 5′&3′-sgRNA and e-sgRNA targeting GFP were introduced into HEK293 cells expressing GFP and Cas9. Both e-sgRNA and 5′&3′-sgRNA exhibited similar activity at relatively high doses (500 ng and 250 ng), and showed higher activity than unmodified sgRNA (Supplementary Fig. 2a) . The e-sgRNA generated higher indel frequencies than 5′&3′-sgRNA at a lower dose. The fact that e-sgRNA and 5′&3′-sgRNA showed similar activity at higher doses when Cas9 protein was already expressed suggests that the binding of Cas9 protein can protect sgRNA from degradation. 
A r t i c l e s
We then compared the editing efficiency of Cas9 mRNA and e-sgRNA, and ribonucleoproteins (RNPs) of Cas9 protein and e-sgRNA. These two combinations generated similar frequencies of indels in HEK293 cells (Supplementary Fig. 2b) .
Evaluate e-sgRNA in vivo
To explore the in vivo application of e-sgRNA, we formulated the GFPtargeting sgRNA into a lipid nanoparticle (LNP) (Fig. 4a) 30 . Editing efficiency in liver tissue was first evaluated in a mouse strain constitutively expressing Cas9 and GFP (Cas9-2A-GFP) 31 . We first compared the efficiency of LNPs formulated with native sgRNA, 5′&3′-sgRNA and e-sgRNA after intravenous injection. After a single injection, unmodified GFP-sgRNA induced a low indel rate at the GFP locus in the liver tissue (~5%), compared with a modest ~22% for 5′&3′-sgRNA. By contrast, e-sgRNA treatment resulted in a significantly higher rate of indels (~46%) than native or 5′&3′-sgRNA (Fig. 4b) . To explore whether repeated dosing of LNP-sgRNA could increase editing events in vivo, we treated mice with two doses of LNP encapsulated e-sgRNA and found a substantial increase in indel frequency (~77%).
To evaluate the in vivo potential of non-viral delivery of e-sgRNA with Cas9 for a therapeutically relevant target, we designed two esgRNAs targeting the mouse proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene (named as PCSK9-1 and PCSK9-2 e-sgRNAs, respectively), a target for the treatment of familial hypercholesterolemia 32 . We encapsulated Cas9 mRNA and both e-sgRNAs in LNPs (Fig. 4c) . Five days after a single intravenous administration of these LNPs, serum Pcsk9 was undetectable (Fig. 4d) , and total cholesterol had decreased 35-40% (Fig. 4e) . We identified a total of 83% ± 3% editing events in the liver genomic DNA, including small indels, a major genomic deletion induced by two sgRNAs and lower levels of inversion (Fig. 4f) . A 55-bp gel shift was clearly shown in the PCR products spanning these two sgRNAs (Supplementary Fig. 3) .
To investigate whether genome editing occurs primarily in hepatocytes or in other cellular populations in the mouse liver, we perfused and digested the livers, isolated hepatic nonparenchymal cells (NPC) and enriched the hepatocyte population 33 . We found indels in total liver tissue and in the enriched hepatocyte population, but not in NPCs (Supplementary Fig. 4 ). These data are consistent with previous observations that the LNP delivery system used in this study is specialized for hepatocytes 30 .
We next compared the efficiency of unmodified, 5′&3′ and esgRNA in vivo PCSK9 editing. Unmodified sgRNA of PCSK9-1 or PCSK9-2 guide sequence resulted in ~5% and ~4% indel formations, and 5′&3′-sgRNA generated ~25% and ~18% indels, respectively (Fig. 4g,h) . In contrast, injection of one e-sgRNA targeting Pcsk9 with Cas9 mRNA resulted in ~65% and ~45% indel formations in the mouse liver, respectively (Fig. 4g,h) . Furthermore, injection of two e-sgRNAs targeting Pcsk9 also induced substantially higher indel frequencies in the mouse liver than treatment with two unmodified or 5′&3′-sgRNAs (Supplementary Fig. 5 ). , Fah (i) and ROSA26 (j) loci in total DNA from liver were measured by TIDE analysis. (n = 6 mice in the e-sgRNA/one dose group of b, n = 5 in Fig. 4j and n = 4 mice in others) *P < 0.05, # P < 0.05 compared to the one dose e-sgRNA-treated group, error bars as s.e.m.
To further evaluate the in vivo potency of e-sgRNA, we synthesized native, 5′&3′ and e-sgRNAs targeting mouse fumarylacetoacetate hydrolase (Fah) and ROSA26 loci. Previously, we have demonstrated efficient LNP-mediated in vivo Cas9 mRNA delivery 12 , but we did not observe substantial indel formation in the mouse liver by co-delivery of Cas9 mRNA and an unmodified Fah sgRNA in FAH mut/mut mice ( Supplementary Fig. 6a,b) . In contrast, e-sgRNA generated >40% indel formations at the Fah locus in FAH mut/mut mice, significantly higher than either unmodified or 5′&3′-sgRNA (~14%) (Fig. 4i) . Notably, for the same Fah guide sequence, the number of indels generated by e-sgRNA is substantially higher than sgRNA expressed by AAV (~24%) 12 . The potency of sgRNAs targeting ROSA26 was evaluated in wild-type mice. e-sgRNA targeting ROSA26 also generated significantly (P < 0.05) higher levels of indels in the mouse liver than unmodified and 5′&3′-sgRNA (Fig. 4j) .
Mice treated with LNP-Cas9 mRNA and Pcsk9 e-sgRNA showed normal liver histology, body weight and serum biochemistry 5 d after dosing (Supplementary Fig. 7a-c) . In addition, histopathology analysis (Supplementary Fig. 7d ) and serum biochemistry (Supplementary Fig. 7e ,f) performed 24 h and 18 d after dosing appeared normal, suggesting no induction of acute or chronic liver toxicity after gene editing. We measured cytokine arrays 24 h after dosing. Whereas most cytokines were not induced after LNP treatment, interleukin (IL)-6 and G-CSF were induced three-to sixfold after LNP-Cas9 mRNA and native sgRNA or 5′&3′-sgRNA, but not after e-sgRNA treatment (Supplementary Fig. 7g ). This may reflect the property of modified RNA to reduce non-specific immune stimulation 34 . To determine whether tissues other than liver were gene edited or not, we measured gene editing efficiency in lung and spleen after treatment of Cas9 and e-sgRNAs targeting Pcsk9 or ROSA26 or Fah. We found undetectable levels of gene editing in the lung and spleen (Supplementary Fig. 8a-c) , indicating the liver specificity of the LNPs used in this study.
We performed GUIDE-Seq 35 to systematically compare the offtarget activity of e-sgRNA programmed SpCas9 relative to other guide systems. Genome-wide off-target analysis was performed in mouse Hepa1-6 cells stably expressing SpCas9 and transfected with: (1) plasmid expressing sgRNAs from a U6 promoter, (2) unmodified sgRNA, (3) 5′&3′-sgRNA or (4) e-sgRNA. Analysis of the off-target peaks recovered for PCSK9-1 guide sequence revealed few off-target sites (1 or 2) in all four treatment groups with similar nuclease activity between the treatment groups (Fig. 5a-c and Supplementary Table 3) . For the PCSK9-2 guide sequence, unmodified, 5′&3′ sgRNA and esgRNA shared many off-target sites and the total number of these was substantially reduced relative to plasmid sgRNA expression (Fig. 5a-c) .
In addition, the bulk activity of the e-sgRNA-programmed SpCas9 across these off-target sites was substantially lower than that observed for plasmid sgRNA expression, which is reflected in an improved specificity ratio. Then we performed deep sequencing to measure the mutation frequency of PCKS9-1 and PCSK9-2's off-target sites from GUIDE-seq, using liver samples from LNP-encapsulated Cas9 mRNA and sgRNA-treated mice. We found no detectable off-target effects in Cas9 with native PCSK9-1 sgRNA-, 5′&3′-sgRNA-or e-sgRNA-treated livers, indicating the high in vivo specificity of this guide sequence ( Fig. 5d and Supplementary Table 4) . We found undetectable indels in all except one off-target site of PCSK9-2. A low frequency of indels (1%) was detected in one off-target site obtained from GUIDE-seq in the livers of e-sgRNA-treated mice, further highlighting the importance of guide sequence selection to minimize off-target effects ( Fig. 5d and Supplementary Table 4) 36 . In our previous studies, we performed GUIDE-Seq for Fah sgRNA, and found that only one site (OT1) passed the stringent criteria for potential cleavage sites by Cas9 (ref. 12). We analyzed the OT1 site in the liver harvested from mice with Fah e-sgRNA and Cas9 treatment, and we found no detectable indels at the OT1 site (Supplementary Fig. 9 ).
DISCUSSION
Using the structure of Cas9-sgRNA complex as a guide, we have identified a number of design criteria that were transferable between different sgRNAs, highlighting the significance of the crystal structure to engineer chemically modified sgRNA. By avoiding modification of 2′OH and phosphate groups in the sgRNA that interact with Cas9 protein, chemical modifications can be made extensively, with ~70% of nucleotides chemically modified. This generalized approach may also be applied to direct comprehensive chemical modifications of sgRNA for other Cas9 proteins, for example, saCas9 (ref. 11), or crRNA in CRISPR-Cfp1 (ref. 37) . Our data also suggest that those 2′OH groups of sgRNA that interact with Cas9 by hydrogen bonding play a key role in the formation of a functional Cas9-sgRNA complex. This is distinct from the RNAi machinery, which does not require the 2′OH of siRNA to activate the RNase activity of RISC complexes 21 . Further studies will be needed to further optimize the modification pattern and to uncover potential sequence-specific effects.
Non-viral genome editing is particularly attractive in a therapeutic setting, given the potential advantages of non-viral delivery systems, including ease of scale-up, speed of customization, lack of pre-existing For the ten off-target sites unique to the e-sgRNA, nine of these sites have peak scores less than 16, which indicates that they are either weak sites or false positives. For reference the target site score is 9,484 (Supplementary Table 3 ). (d) Off-target sites obtained from GUIDEseq were amplified using liver samples from mice treated with LNPencapsulated Cas9 mRNA, PCSK9-1 and PCSK9-2 sgRNA. Deep-seq was performed to determine mutation frequency. The bars indicate total indel frequencies at the off-target sites. n = 3 mice, error bars as s.e.m.
immunity, and the possibility for limiting exposure to nuclease, among other items 14, 20 . Here we demonstrate that appropriate chemically modified sgRNA enables very efficient in vivo (up to >80%), non-viral vector-mediated genome editing. A number of factors complicate accurate quantification: (1) larger-deletion-bearing alleles will possibly amplify more efficiently, although two differently sized PCR amplicons showed similar deletion of a 55-bp genomic sequence (Supplementary Fig. 3) . ( 2) The LNP used here is largely hepatocytespecific 30 , but only ~70-80% percent of the cells in a mouse liver are hepatocytes 38 . Since a large portion of hepatocytes are polyploid 39 , we estimate that hepatocytes account for >80% of total genome copies in the liver 38, 39 and show that the majority of gene editing occurred in hepatocytes (Supplementary Fig. 4) . The LNP-mediated co-delivery of Cas9 mRNA and e-sgRNA (LNP-CRISPR) successfully depleted a disease-related protein through creating high levels of indels at the corresponding genomic locus, suggesting its potential for disease treatment (Fig. 4) . We note that LNP-mediated siRNA therapy has been evaluated in phase 3 trials and the results are positive 20 . Non-viral genome editing with Cas9 has a number of potential advantages compared with siRNA therapies. First among these, is that a single dose of LNP-CRISPR may provide for long-term therapeutic effects or potentially curative therapy, decreasing or likely eliminating the need for repeated injections. Non-viral delivery of Cas9 as mRNA limits the exposure of the genome to Cas9, decreasing the potential for side effects relative to viral systems where the Cas9 gene is present for months or longer. A number of diseases demand correction or knock-in of sequences 12 . The applications of e-sgRNA to HDR and/or homology-independent targeted integration (HITI) are worth further investigations 40 . Beyond LNP delivery, we believe that these same types of modifications may facilitate delivery of e-sgRNA as a ligand-conjugate form without the need for encapsulation 20 .
Besides the potential therapeutic applications of e-sgRNA, we anticipate that the highly modified sgRNA could be integrated into a range of CRISPR-associated technologies such as CRISPR-mediated imaging, activation and inhibition of targeted genes 41 . We believe that the ability to use nanoparticles to permanently modify the genome of living animals opens the door to a range of therapeutic and industrial applications, and further advances the utility of the Cas9 genome editing system.
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